BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Still's Disease readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Still's Disease\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07203001-11265@assetmemo.bio
DTSTAMP:20261121T004110Z
DTSTART;VALUE=DATE:20270422
DTEND;VALUE=DATE:20270423
SUMMARY:Arumakimig: Phase 2 readout est. (NCT07203001)
DESCRIPTION:Arumakimig\, phase 2\, Still's Disease.\nStudy: A Phase II Tria
 l to Evaluate the Clinical Efficacy\, Safety and Tolerability of MAS825 in
  Pediatric and Adult Participants With Still's Disease\nEstimated primary 
 completion: 22 April 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/arumakimig#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07203001
URL:https://assetmemo.bio/drug/arumakimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
